HomePLX • NYSEAMERICAN
add
Protalix Biotherapeutics Inc
Previous close
$1.16
Day range
$1.13 - $1.16
Year range
$1.03 - $2.51
Market cap
83.58M USD
Avg Volume
468.12K
P/E ratio
11.31
Dividend yield
-
Financials
Income Statement
Revenue
Net income
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Revenue | 3.75M | -60.91% |
Operating expense | 6.00M | -33.03% |
Net income | -4.60M | -46.76% |
Net profit margin | -122.60 | -275.38% |
Earnings per share | — | — |
EBITDA | -4.53M | -108.08% |
Effective tax rate | 2.92% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 48.49M | 46.77% |
Total assets | 89.82M | 34.96% |
Total liabilities | 60.04M | -8.41% |
Total equity | 29.79M | — |
Shares outstanding | 73.32M | — |
Price to book | 2.83 | — |
Return on assets | -13.93% | — |
Return on capital | -20.93% | — |
Cash Flow
Net change in cash
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Net income | -4.60M | -46.76% |
Cash from operations | 4.19M | 239.69% |
Cash from investing | -606.00K | -112.81% |
Cash from financing | — | — |
Net change in cash | 3.58M | -77.55% |
Free cash flow | 4.97M | 362.14% |
About
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease. Wikipedia
CEO
Founded
1993
Headquarters
Website
Employees
208